Despite promising clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable opposition from pharmacy benefit managers. These companies https://joanvgmo688868.getblogs.net/74665168/company-s-vyndamax-faces-is-meeting-pbm-obstacles-the-look-of-reimbursement-battles